{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:15:20Z","timestamp":1792790120561,"version":"4.5.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Sepsis is a systemic condition caused by a dysregulated host response to infection and often associated with excessive release of proinflammatory cytokines resulting in multi-organ failure (MOF), including cardiac dysfunction. Despite a number of effective supportive treatments (e.g. ventilation, dialysis), there are no specific interventions that prevent or reduce MOF in patients with sepsis. To identify possible intervention targets, we re-analyzed the publicly accessible Gene Expression Omnibus accession GSE131761 dataset, which revealed an increased expression of spleen tyrosine kinase (<jats:italic>SYK<\/jats:italic>) in the whole blood of septic patients compared to healthy volunteers. This result suggests a potential involvement of SYK in the pathophysiology of sepsis. Thus, we investigated the effects of the highly selective SYK inhibitor PRT062607 (15mg\/kg; i.p.) on sepsis-induced cardiac dysfunction and MOF in a clinically-relevant, murine model of sepsis. PRT062607 or vehicle (saline) was administered to 10-weeks-old C57BL\/6 mice at 1h after the onset of sepsis induced by cecal ligation and puncture (CLP). Antibiotics (imipenem\/cilastatin; 2mg\/kg; s.c.) and analgesic (buprenorphine; 0.05mg\/kg; i.p.) were administered at 6h and 18h post-CLP. After 24h, cardiac function was assessed <jats:italic>in vivo<\/jats:italic> by echocardiography and, after termination of the experiments, serum and cardiac samples were collected to evaluate the effects of SYK inhibition on the systemic release of inflammatory mediators and the degree of organ injury and dysfunction. Our results show that treatment of CLP-mice with PRT062607 significantly reduces systolic and diastolic cardiac dysfunction, renal dysfunction and liver injury compared to CLP-mice treated with vehicle. In addition, the sepsis-induced systemic inflammation (measured as an increase in inflammatory cytokines and chemokines in the serum) and the cardiac activation of NF-kB (IKK) and the NLRP3 inflammasome were significantly reduced in CLP-mice treated with PRT062607. These results demonstrate, for the first time, that SYK inhibition 1h after the onset of sepsis reduces the systemic inflammation, cardiac dysfunction and MOF, suggesting a potential role of the activation of SYK in the pathophysiology of sepsis. Novel therapeutic strategies that inhibit SYK activity may be of benefit in patients with diseases associated with local or systemic inflammation including sepsis.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1447901","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:27:12Z","timestamp":1730694432000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Spleen tyrosine kinase: a novel pharmacological target for sepsis-induced cardiac dysfunction and multi-organ failure"],"prefix":"10.3389","volume":"15","author":[{"given":"Chiara","family":"Verra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Kerstin","family":"Paulmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamila","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Marzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Ferreira Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Collino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina Maren","family":"Coldewey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thiemermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"ofy313","DOI":"10.1093\/ofid\/ofy313","article-title":"Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit","volume":"5","author":"Sakr","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/J.MPSUR.2015.08.002","article-title":"Sepsis in the intensive care unit","volume":"33","author":"Bennett","year":"2015","journal-title":"Surg (Oxford Oxfordshire)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"F1000RESEARCH","DOI":"10.12688\/F1000RESEARCH.15758.1\/DOI","article-title":"Recent advances in understanding and managing sepsis [version 1; peer review: 3 approved","volume":"7","author":"Berg","year":"2018","journal-title":"F1000Research"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA - J Am Med Assoc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003865","article-title":"Left ventricular systolic longitudinal function as predictor of outcome in patients with sepsis","volume":"8","author":"Palmieri","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"B7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/CIRCULATIONAHA.106.678359","article-title":"Sepsis and the heart","volume":"116","author":"Merx","year":"2007","journal-title":"Circulation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40779-016-0099-9","article-title":"Pathophysiology of sepsis-induced myocardial dysfunction","volume":"3","author":"Lv","year":"2016","journal-title":"Mil Med Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1037","article-title":"The septic heart: current understanding of molecular mechanisms and clinical implications","volume":"155","author":"Martin","year":"2019","journal-title":"Chest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/S13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-018-5085-0","article-title":"The surviving sepsis campaign bundle: 2018 update","volume":"44","author":"Levy","year":"2018","journal-title":"Intensive Care Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7861\/CLINMEDICINE.18-2-146","article-title":"Diagnosis and management of sepsis","volume":"18","author":"Evans","year":"2018","journal-title":"Clin Med (Northfield Il)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2022.104363","article-title":"Immunopathophysiology of human sepsis","volume":"86","author":"Wiersinga","year":"2022","journal-title":"eBioMedicine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/J.BJID.2020.09.004","article-title":"Molecular mechanisms of organ damage in sepsis: an overview","volume":"24","author":"Sygitowicz","year":"2020","journal-title":"Braz J Infect Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/FCELL.2019.00108","article-title":"Sepsis: inflammation is a necessary evil","volume":"7","author":"Nedeva","year":"2019","journal-title":"Front Cell Dev Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.21037\/JTD.2018.11.74","article-title":"Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine","volume":"11","author":"Mehta","year":"2019","journal-title":"J Thorac Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.949","article-title":"Tumor necrosis factor \u03b1 and interleukin 1\u03b2 are responsible for in vitro myocardial cell depression induced by human septic shock serum","volume":"183","author":"Kumar","year":"1996","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/S40560-016-0148-1","article-title":"Sepsis-induced myocardial dysfunction: pathophysiology and management","volume":"4","author":"Kakihana","year":"2016","journal-title":"J Intensive Care"},{"key":"B19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1073\/PNAS.0401602101","article-title":"The immunomodulatory adapter proteins DAP12 and Fc receptor \u03b3-chain (FcR\u03b3) regulate development of functional osteoclasts through the Syk tyrosine kinase","volume":"101","author":"M\u00f3csai","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.1079477","article-title":"Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk","volume":"299","author":"Abtahian","year":"2003","journal-title":"Science"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000489863","article-title":"Spleen tyrosine kinase as a target therapy for pseudomonas aeruginosa infection","volume":"10","author":"Alhazmi","year":"2018","journal-title":"J Innate Immun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1139\/CJPP-2017-0307","article-title":"Syk inhibitor R406 downregulates inflammation in an in vitro model of Pseudomonas aeruginosa infection","volume":"96","author":"Alhazmi","year":"2018","journal-title":"Can J Physiol Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1189\/JLB.3HI0814-371RR","article-title":"Syk is involved in NLRP3 inflammasome-mediated caspase-1 activation through adaptor ASC phosphorylation and enhanced oligomerization","volume":"97","author":"Lin","year":"2015","journal-title":"J Leukoc Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/NATURE07965","article-title":"Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence","volume":"459","author":"Gross","year":"2009","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/J.1476-5381.2012.02097.X","article-title":"The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL","volume":"167","author":"Miller","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.767366","article-title":"Syk-myD88 axis is a critical determinant of inflammatory-response in activated macrophages","volume":"12","author":"Yi","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ART.23992","article-title":"Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial","volume":"58","author":"Weinblatt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ART.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ART.27452","article-title":"Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice","volume":"62","author":"Deng","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/INTIMM\/DXS078","article-title":"Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis","volume":"24","author":"Ozaki","year":"2012","journal-title":"Int Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"105408","DOI":"10.1016\/j.jbc.2023.105408","article-title":"Spleen Tyrosine Kinase phosphorylates VE-cadherin to cause endothelial barrier disruption in acute lung injury","volume":"299","author":"Shadab","year":"2023","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/JCPH.794","article-title":"PRT062607 achieves complete inhibition of the spleen tyrosine kinase at tolerated exposures following oral dosing in healthy volunteers","volume":"57","author":"Coffey","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1124\/JPET.112.200832\/-\/DC1","article-title":"The selective syk inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemias","volume":"344","author":"Spurgeon","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1124\/JPET.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/J.JINF.2021.05.039","article-title":"Distinguishing septic shock from non-septic shock in postsurgical patients using gene expression","volume":"83","author":"Mart\u00ednez-Paz","year":"2021","journal-title":"J Infect"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2012.02.010","article-title":"Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research","volume":"20","author":"Kilkenny","year":"2012","journal-title":"Osteoarthr Cartil"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-7-233","article-title":"A robust scoring system to evaluate sepsis severity in an animal model","volume":"7","author":"Shrum","year":"2014","journal-title":"BMC Res Notes"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2023.1223014","article-title":"Baricitinib protects mice from sepsis-induced cardiac dysfunction and multiple-organ failure","volume":"14","author":"Verra","year":"2023","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.3791\/2860","article-title":"Cecal ligation puncture procedure","volume":"51","author":"Toscano","year":"2011","journal-title":"J Vis Exp"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.581758","article-title":"X-linked immunodeficient mice with no functional bruton\u2019s tyrosine kinase are protected from sepsis-induced multiple organ failure","volume":"11","author":"O\u2019Riordan","year":"2020","journal-title":"Front Immunol"},{"key":"B43","volume-title":"R: A language and environment for statistical computing","year":"2023"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70061-X","article-title":"Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit","volume":"2","author":"Vincent","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMP1707170","article-title":"Recognizing sepsis as a global health priority - A WHO resolution","volume":"377","author":"Reinhart","year":"2017","journal-title":"N Engl J Med"},{"key":"B46","unstructured":"TavlesseEuropean Medicines Agency"},{"key":"B47","unstructured":"FDA approves fostamatinib tablets for ITPFDA"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/RHEUMATOLOGY\/KEAA732","article-title":"Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study","volume":"60","author":"Tanaka","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ART.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2019.00897","article-title":"Efficacy and safety of multiple dosages of fostamatinib in adult patients with rheumatoid arthritis: A systematic review and meta-analysis","volume":"10","author":"Kang","year":"2019","journal-title":"Front Pharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2131751","DOI":"10.1080\/09537104.2022.2131751","article-title":"Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib","volume":"34","author":"Cooper","year":"2023","journal-title":"Platelets"},{"key":"B52","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1124\/JPET.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/PRP2.175","article-title":"In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib","volume":"3","author":"Rolf","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/S40262-022-01135-0\/TABLES\/5","article-title":"Clinical pharmacokinetics and pharmacodynamics of fostamatinib and its active moiety R406","volume":"61","author":"Matsukane","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"B55","article-title":"Modeling sepsis in the laboratory: Merging sound science with animal well-being","volume":"58","author":"Nemzek","year":"2008","journal-title":"Comp Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2016.021","article-title":"Current murine models of sepsis","volume":"17","author":"Lewis","year":"2016","journal-title":"Surgical Infections (Larchmt)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4161\/viru.26083","article-title":"Animal models of sepsis","volume":"5","author":"Fink","year":"2014","journal-title":"Virulence"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACC.2018.08.2162","article-title":"Ejection fraction pros and cons: JACC state-of-the-art review","volume":"72","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4103\/0971-9784.192617","article-title":"Left ventricular global systolic function assessment by echocardiography","volume":"19","author":"Chengode","year":"2016","journal-title":"Annals of Cardiac Anaesthesia"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00339.2017","article-title":"Guidelines for measuring cardiac physiology in mice","volume":"314","author":"Lindsey","year":"2018","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the european association of cardiovascular imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J Am Soc Echocardiogr"},{"key":"B62","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1540-8175.2011.01575.x","article-title":"Improvement of myocardial performance (Tei) index closely reflects intrinsic improvement of cardiac function: assessment in revascularized hibernating myocardium","volume":"29","author":"Carluccio","year":"2012","journal-title":"Echocardiography"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-016-0839-7","article-title":"Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study","volume":"32","author":"Biering-S\u00f8rensen","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"B64","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/CCM.0000000000002065","article-title":"Relative bradycardia in patients with septic shock requiring vasopressor therapy","volume":"45","author":"Beesley","year":"2017","journal-title":"Crit Care Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199210000-00006","article-title":"Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group","volume":"20","author":"Clemmer","year":"1992","journal-title":"Crit Care Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199210000-00002","article-title":"Prognostic factors in sepsis: the cold facts","volume":"20","author":"Balk","year":"1992","journal-title":"Crit Care Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/J.CCC.2017.08.003","article-title":"Mechanisms of organ dysfunction in sepsis","volume":"34","author":"Pool","year":"2018","journal-title":"Crit Care Clin"},{"key":"B69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-1-62703-290-2_7","article-title":"Detection of necrosis by release of lactate dehydrogenase activity","volume":"979","author":"Chan","year":"2013","journal-title":"Methods Mol Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.1994.11741153","article-title":"Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities","volume":"6","author":"Bacci","year":"1994","journal-title":"J Chemother"},{"key":"B71","first-page":"629","article-title":"Focus: death: organ dysfunction in sepsis: an ominous trajectory from infection to death","volume":"92","author":"Caraballo","year":"2019","journal-title":"Yale J Biol Med"},{"key":"B72","unstructured":"Alanine amino transferase (ALT)\n            MorilesKE\n            AzerSA\n          StatPearls Publishing2020"},{"key":"B73","unstructured":"BUN and creatinine\n            HostenAO\n          Butterworths1990"},{"key":"B74","volume-title":"Renal function tests","author":"Gounden","year":"2020"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.2147\/CMAR.S199260","article-title":"Prognostic significance of serum lactate dehydrogenase in patients with breast cancer: a meta-analysis","volume":"11","author":"Liu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0007182","article-title":"Rhabdomyolysis in community acquired bacterial sepsis \u2013 A retrospective cohort study","volume":"4","author":"Kumar","year":"2009","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0009017","article-title":"Elevated cardiac troponin I in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis","volume":"5","author":"Altmann","year":"2010","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2014.03.028","article-title":"Myocardial depression in sepsis: From pathogenesis to clinical manifestations and treatment","volume":"29","author":"Antonucci","year":"2014","journal-title":"J Crit Care"},{"key":"B79","doi-asserted-by":"publisher","first-page":"E1715","DOI":"10.21037\/JTD.2016.12.82","article-title":"Prevention of organ dysfunction in septic shock: still looking for an effective treatment","volume":"8","author":"Landoni","year":"2016","journal-title":"J Thorac Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/S13054-015-0794-Z","article-title":"Optimizing mean arterial pressure in septic shock: a critical reappraisal of the literature","volume":"19","author":"Leone","year":"2015","journal-title":"Crit Care"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/JCSM.12763","article-title":"Inhibition of the NLRP3\/IL-1\u03b2 axis protects against sepsis-induced cardiomyopathy","volume":"12","author":"Busch","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/J.NIOX.2018.09.005","article-title":"Sulfur dioxide attenuates sepsis-induced cardiac dysfunction via inhibition of NLRP3 inflammasome activation in rats","volume":"81","author":"Yang","year":"2018","journal-title":"Nitric Oxide Biol Chem"},{"key":"B83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/S00395-017-0603-8","article-title":"Carbon monoxide releasing molecule-3 improves myocardial function in mice with sepsis by inhibiting NLRP3 inflammasome activation in cardiac fibroblasts","volume":"112","author":"Zhang","year":"2017","journal-title":"Basic Res Cardiol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1681\/ASN.2015060670","article-title":"I\u03baB kinase inhibitor attenuates sepsis-induced cardiac dysfunction in CKD","volume":"28","author":"Chen","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1086\/374750","article-title":"Nuclear factor-kappaB and its role in sepsis-associated organ failure","volume":"187","author":"Abraham","year":"2003","journal-title":"J Infect Dis"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1242\/DMM.012435","article-title":"Inhibition of I\u03baB kinase reduces the multiple organ dysfunction caused by sepsis in the mouse","volume":"6","author":"Coldewey","year":"2013","journal-title":"Dis Model Mech"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet (London England)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/J.BIOCEL.2008.08.011","article-title":"Distinct role of spleen tyrosine kinase in the early phosphorylation of inhibitor of kappaB alpha via activation of the phosphoinositide-3-kinase and Akt pathways","volume":"41","author":"Lee","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"781235","DOI":"10.1155\/2010\/781235","article-title":"Toll-like receptor signaling pathways\u2013therapeutic opportunities","volume":"2010","author":"Mohan","year":"2010","journal-title":"Mediators Inflammation"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-009-0024-y","article-title":"The role of IL-1 in the pathogenesis of heart disease","volume":"57","author":"Bujak","year":"2009","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3182186d27","article-title":"Myocardial depressant effects of interleukin 6 in meningococcal sepsis are regulated by p38 mitogen-activated protein kinase","volume":"39","author":"Pathan","year":"2011","journal-title":"Crit Care Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/S12265-016-9703-3","article-title":"CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study","volume":"9","author":"Altara","year":"2016","journal-title":"J Cardiovasc Transl Res"},{"key":"B93","first-page":"669","article-title":"Role of cytokines as a double-edged sword in sepsis","volume":"27","author":"Chaudhry","year":"2013","journal-title":"In Vivo"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203239","article-title":"Activators and target genes of Rel\/NF-\u03baB transcription factors","volume":"18","author":"Pahl","year":"1999","journal-title":"Oncogene 1999 1849"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct Target Ther 2017 21"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/J.FEBSLET.2012.02.045","article-title":"TLR-induced NF-\u03baB activation regulates NLRP3 expression in murine macrophages","volume":"586","author":"Qiao","year":"2012","journal-title":"FEBS Lett"},{"key":"B97","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/NYAS.12458","article-title":"Mechanism of NLRP3 inflammasome activation","volume":"1319","author":"Sutterwala","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"B98","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/CR.2010.177","article-title":"Non-canonical NF-\u03baB signaling pathway","volume":"21","author":"Sun","year":"2011","journal-title":"Cell Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"H1025","DOI":"10.1152\/AJPHEART.00795.2013","article-title":"Interleukin-18 mediates interleukin-1-induced cardiac dysfunction","volume":"306","author":"Toldo","year":"2014","journal-title":"Am J Physiol - Hear Circ Physiol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PPAT.1000559","article-title":"Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases","volume":"5","author":"Tiemi Shio","year":"2009","journal-title":"PloS Pathog"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.837180\/BIBTEX","article-title":"Pharmacological inhibition of FAK-pyk2 pathway protects against organ damage and prolongs the survival of septic mice","volume":"13","author":"Alves","year":"2022","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1038\/NI.2749","article-title":"Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity","volume":"14","author":"Hara","year":"2013","journal-title":"Nat Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02129","article-title":"Bruton\u2019s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice","volume":"10","author":"O\u2019Riordan","year":"2019","journal-title":"Front Immunol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.900906\/BIBTEX","article-title":"RG100204, A novel aquaporin-9 inhibitor, reduces septic cardiomyopathy and multiple organ failure in murine sepsis","volume":"13","author":"Mohammad","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1447901\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T04:27:23Z","timestamp":1730694443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1447901\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":105,"alternative-id":["10.3389\/fimmu.2024.1447901"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1447901","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"article-number":"1447901"}}